Delivery Order SPE2DB20D3303-SPE2DB25FA2TG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $23,388.90 to AmerisourceBergen Drug Corp for Actemra 162 mg/0.9 mL syringes with a completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child contract under a larger vehicle. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 12, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $4,594.53. This firm fixed-price, competitively awarded delivery order is funded by the Defense Logistics Agency's Medical Supply Chain, a defense-focused federal agency, and has an ultimate completion date of August 13, 2025. The award was made under no set-aside designation,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,328.29 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract reflects a firm fixed price arrangement with an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, consistent with the vendor's track...
- The Defense Logistics Agency awarded a $3,729.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 200 mg/10 mL vials. The contract, which is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This award was made through open competition with no set-aside designation, reflecting...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11,660.75 by the Defense Logistics Agency (DLA) on August 1, 2025. The contract, which is not set-aside and competitively awarded under a firm fixed-price structure, calls for delivery of Actemra Actpen 162 mg/0.9 mL injectable medication with a completion date of August 4, 2025. The place of performance is the company's Conshohocken, Pennsylvania...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 26, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes valued at $5,945.97 with a firm fixed price structure. The contract specifies a completion date of July 28, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This is an unrestricted, competitively awarded delivery order with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $11,196.02 to AmerisourceBergen Drug Corp for 4,568,895,450 units of Actemra 400 mg/20 mL vials on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract utilizes firm fixed pricing with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2TGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion comprehensive pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies an extensive range of medications, vaccines, and medical supplies to support military healthcare systems and federal medical procurement needs. The company's federal contracting portfolio demonstrates consistent capability in delivering both brand-name and generic pharmaceuticals across multiple therapeutic domains through DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.3k | 8/19/25 |